Ionis Pharmaceuticals SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 9, 2026, 7 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedIonis Pharmaceuticals Q3 2026 revenue of $243 million and GAAP EPS of -$0.66 beat consensus, but TRYNGOLZA 2026 sales guidance cut to about $50 million
8-KOct. 23, 2026, 1:41 p.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedIonis Pharmaceuticals Partner Roche Reports 43.1% Proteinuria Reduction for Sefaxersen in Phase 3 IgAN Study
8-KOct. 21, 2026, 4:15 p.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedIonis Pharmaceuticals' partner GSK wins FDA approval of Hibsago (bepirovirsen) for chronic hepatitis B, with Ionis earning royalties of 10-12% on net sales
8-KSept. 23, 2026, 6:03 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
8-KSept. 4, 2026, 5 p.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
8-KSept. 4, 2026, 6:01 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
8-KJuly 29, 2026, 7:31 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits